Insider Selling: ResMed (NYSE:RMD) CEO Sells $1,175,102.55 in Stock

Posted by Brian Himes on Nov 12th, 2026

ResMed Inc. (NYSE:RMD – Get Free Report) CEO Michael Farrell sold 4,993 shares of ResMed stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $235.35, for a total value of $1,175,102.55. Following the completion of the sale, the chief executive officer directly owned 479,803 shares in the company, valued at $112,921,636.05. This trade represents a 1.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ResMed Price Performance

NYSE:RMD opened at $238.27 on Thursday. The business’s 50-day moving average is $231.83 and its 200 day moving average is $224.58. ResMed Inc. has a 12 month low of $180.26 and a 12 month high of $277.67. The company has a market capitalization of $33.52 billion, a P/E ratio of 20.30, a P/E/G ratio of 1.42 and a beta of 0.77. The company has a current ratio of 2.65, a quick ratio of 1.88 and a debt-to-equity ratio of 0.04.

ResMed (NYSE:RMD – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The medical equipment provider reported $2.91 earnings per share for the quarter, beating the consensus estimate of $2.67 by $0.24. ResMed had a return on equity of 26.42% and a net margin of 27.79%. The business had revenue of $1.41 billion during the quarter, compared to analysts’ expectations of $1.39 billion. During the same quarter last year, the business posted $2.55 EPS. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. On average, equities research analysts forecast that ResMed Inc. will post 12.14 earnings per share for the current fiscal year.

ResMed Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 17th. Stockholders of record on Thursday, November 12th will be given a dividend of $0.66 per share. This represents a $2.64 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Thursday, November 12th. ResMed’s dividend payout ratio is currently 24.04%.

Hedge Funds Weigh In On ResMed

Hedge funds have recently added to or reduced their stakes in the company. Advisors Asset Management Inc. bought a new stake in ResMed in the third quarter worth about $2,831,000. Voya Investment Management LLC lifted its stake in shares of ResMed by 0.5% during the 3rd quarter. Voya Investment Management LLC now owns 33,766 shares of the medical equipment provider’s stock worth $7,466,000 after acquiring an additional 166 shares during the last quarter. Bogart Wealth LLC boosted its holdings in ResMed by 1.3% during the 3rd quarter. Bogart Wealth LLC now owns 25,582 shares of the medical equipment provider’s stock valued at $5,656,000 after acquiring an additional 319 shares during the period. Paralel Advisors LLC grew its position in ResMed by 1.1% in the 3rd quarter. Paralel Advisors LLC now owns 10,410 shares of the medical equipment provider’s stock valued at $2,302,000 after acquiring an additional 117 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its stake in ResMed by 26.0% in the third quarter. Allspring Global Investments Holdings LLC now owns 10,972 shares of the medical equipment provider’s stock worth $2,427,000 after purchasing an additional 2,267 shares during the period. 54.98% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Mizuho set a $270.00 price target on shares of ResMed in a research report on Friday, October 30th. Needham & Company LLC reiterated a “hold” rating on shares of ResMed in a research report on Friday, October 30th. UBS Group reissued a “buy” rating and issued a $300.00 price objective on shares of ResMed in a research note on Tuesday, July 21st. Wells Fargo & Company upped their target price on shares of ResMed from $215.00 to $250.00 and gave the company an “equal weight” rating in a research report on Friday, October 30th. Finally, Citigroup increased their price target on shares of ResMed from $240.00 to $270.00 and gave the company a “neutral” rating in a report on Friday, October 30th. Seven analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $253.69.

Check Out Our Latest Analysis on RMD

ResMed Company Profile

(Get Free Report)

ResMed is a medical technology company that develops products and software for people with sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its devices include continuous positive airway pressure (CPAP) and bilevel machines, ventilators and related masks and accessories. The company also provides cloud-connected software for managing sleep and respiratory care, along with digital tools used by home medical equipment providers and post-acute care organizations.